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For more than 2000 years, the use of pharmaceutical substances—especially of 
botanical drugs—has been the central therapeutic approach pursued by Chinese 
medicine. A large country like China with its diverse geographical zones has an 
enormous wealth of plants. About 7,000 botanical species, almost 20 percent of 
the Chinese flora, have found their way into Chinese traditional materia medica.  
When Chinese herbal therapies became popular in the West in the 1990s, 
many patients and physicians, in Europe at least, were still using herbal remedies 
from the European tradition of “phytotherapy” in their daily health care. Con-
sumers consider these substances to be a “natural” medication, and prefer them to 
synthetic pharmaceutical drugs. They are convinced that consuming herbal drugs 
is less risky for their health. So, when phytotherapy with Chinese herbs was of-
fered, it was accepted almost uncritically. In some cases, though, this proved to 
be dangerous, as the Chinese herbs, at that time, had not been subjected to the 
same amount of research as those herbs used in Western medicine that had be-
come part of the European official pharmacopoeia. 
The trust in Chinese botanical drugs was shaken when first reports of adverse 
effects caused by slimming pills containing the drug Han fangji 漢 防 己 (Steph-
ania tetrandra S.Moore) appeared in the Western media in the early 1990s. Han 
fangji was accused of inducing renal failure. Chromatographic studies showed 
that the drug had been confused with another drug, i.e. Guang fangji 廣 防 己 
(Aristolochia Fangji). Both are assigned colloquially the same name: Fangji 防 
己. 
Most adverse effects of Chinese botanical drugs can be traced to ignorance 
and bad quality. For the Chinese practitioner, the outside appearance of a drug, 
that is, a combination of a traditionally defined aesthetic quality and its careful 
preparation, is most important. The determinants of drug quality that are crucial 
in Western pharmacology, namely identity, purity, and contamination, are not 
decisive for the Chinese practitioner when he buys a drug on the drug market. 
Besides adulteration and contamination, misidentification is an important prob-
lem for Western and Chinese practitioners. In Chinese traditional materia medica 
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one name can be given to different botanical drugs, and one and the same herbal 
substance may be traded under different names. 
Practitioners of Chinese Medicine in Asia and in the West tend to overlook 
the potential of the intrinsic toxicity of botanical drugs, and consumers may not 
be aware of this danger. A botanical drug can contain more than one hundred 
constituents. Their synergistic effects, that is, their chemical interaction in the 
human organism after consumption, are rarely known. 
Chinese medical practitioners, pharmacists, and researchers find a great deal 
of data on the therapeutic properties of Chinese herbs in the traditional literary 
sources. Formularies, fangshu 方 書, constitute the historically most important 
literary genre of clinical Chinese medicine. They contain innumerable collections 
of combinations of drugs known to be effective and passed on for centuries, if not 
millennia, as proved recipes. Of similar importance are the so-called bencao 本 
草 works, i.e. collections of descriptions of the properties of individual drugs. 
The problem for the Western researcher or practitioner is the language. For ex-
ample, the largest historical encyclopaedia of Chinese materia medica, the Ben-
cao gangmu 本 草 綱 目, “Materia Medica Arranged According to Monographs 
and Single Criteria” (1596), by Li Shizhen, is available in Chinese and Japanese 
only, but remains inaccessible to most Western readers.  
Since the 1950s, the PRC has engaged in research on Chinese materia medica. 
This includes the collection of plant materials, studies in pharmacognosy, a 
search for active constituents, pharmacological research, and attempts at a verifi-
cation of traditional indications. At the same time, guidelines for quality control 
of botanical substances, as well as for preparing and manufacturing traditional 
herbal remedies, have been issued. In this regard, the publication of the Adminis-
trative Law on the Drug Code of 1985 was a major milestone. 
A series of official Pharmacopoeias of the People’s Republic of China, the 
Zhonghua renmin gongheguo yaodian 中 华 人 民 共 和 国 药 典, reflects many 
of these initiatives. The first edition was published in 1977. The first of its two 
volumes was devoted to crude drugs and preparations from crude drugs, the se-
cond volume offered data on synthetic pharmaceutical substances. Since 1980, a 
revised and supplemented Chinese Pharmacopoeia has been published every five 
years. In 1992, for the first time, an English edition of the Chinese Pharmacopoe-
ia was issued. 
A pioneer work, the Pharmacology and Applications of Chinese Materia 
Medica was published by Chang and But in two volumes in 1986. This work 
offers material collected by a committee during 1978-1979, and was reviewed by 
the Chinese Society for Pharmacology before its publication in Chinese in 1983. 
The first English edition was issued in 1986; identical reprints appeared in 1996, 
1998, and 2001. 
The two volumes contain monographs of 250 items of Chinese materia medi-
ca: 231 herbal, 18 animal, and 1 mineral drug. The description of the drugs fol-
lows the information given in the “Pharmacopoeia of the People’s Republic of 
China” of 1977. The names of the drugs are given in pinyin romanisation. They 
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are listed according to the number of strokes of their first Chinese character. An 
index of scientific names is provided at the end of the second volume. 
Each monograph is divided into six entries: 
1. Source. This section provides: 
- The Chinese name, Chinese characters, botanical name, and the part of the plant 
being used. In some cases, alternative names of the plant are mentioned. 
- Flavour, thermoquality, actions, and indications ascribed to a drug by traditional 
Chinese pharmacology. 
- Botanical subspecies of the drug which alternatively could be used in different 
Chinese provinces.  
2. Chemical composition. 
3. Pharmacology, including toxicity.  
4. Clinical studies. 
5. Adverse effects. 
6. References. These references quote research articles since the 1940s regarding 
chemical constituents, pharmacology, clinical studies, etc. 
Three indexes of botanical names, pharmacological actions, and Chinese drug 
names are added at the end of each volume. 
Reflecting research policy pursued in the PRC, the emphasis of this work is 
on Western pharmacology and clinical studies. The authors clearly indicate that 
an integration of Chinese and Western medicine is aimed at, with Western medi-
cine taking the lead. In a preface, it is stated that the book is meant to be a refer-
ence work for the Western reader and that therefore it mentions only those as-
pects that correspond to Western scientific thought. Scientific terms are con-
sistent with those in the “Index Medicus,” “Chemical Abstracts,” and the leading 
botanical journals. The preface for the Chinese reader states, that “traditionally 
ascribed actions are omitted in the English edition.” 
Chang and But quote data from both modern Western medicine and tradition-
al Chinese pharmacology, that is, the primary qualities ascribed to botanical 
drugs in the traditional literary sources, i.e. flavour and thermoquality, are given. 
Thus, it is possible to assign to botanical drugs the traditional pharmacological 
effects as well. These parameters provide a link to Chinese traditional pharma-
ceutical literature from before the time when commissions in the PRC began to 
rationalize the body of Chinese traditional medicine in the 1950s. In this respect, 
this work differs from most of the scientific publications in English.  
The difference between Chinese medicine and Western medicine is alluded to, 
for example, by designating organs such as “kidneys,” shen 腎, and “spleen,” pi 
脾, in quotes to indicate that these are not Western biomedical terms but concepts 
from traditional Chinese medicine. 
Modern readers interested in this work as a reference book should be aware 
that they are consulting a historical work dating from the time of the first Phar-
macopoeia of the PRC, i.e. from 1977. The references to clinical pharmacologi-
cal studies given at the end of each monograph start from the forties of the last 
century and end with the seventies. Since that time, a great deal of research has 
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been done on Chinese materia medica that has not been included in any of the 
reprints of this work. Paul But is a well known researcher in botany and biology. 
Molecular biology plays an important role in his studies on Chinese flora and 
Chinese herbal medicine. For further information, interested readers should turn 
to his publications since the 1990s. But’s numerous articles in journals on phar-
maceutics and chemistry demonstrate his interest in creating “rational” botanical 
drugs, i.e. herbal remedies whose quality, chemical constituents, and intrinsic as 
well as extrinsic toxicity are known through pharmacological research. It is only 
by applying this approach that it is possible to compare the use of Chinese mate-
ria medica in Western and Chinese medicine, and to legitimate their therapeutic 
indications. 
